.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Zolmitriptan - Generic Drug Details

« Back to Dashboard
Zolmitriptan is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Ltd, Astrazeneca, Alembic Pharms Ltd, Macleods Pharms Ltd, Ajanta Pharma Ltd, Jubilant Generics, Glenmark Generics, Teva Pharms Usa, IPR, Apotex Inc, Sun Pharma Global, Invagen Pharms, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for zolmitriptan. Nineteen suppliers are listed for this compound.

Summary for Generic Name: zolmitriptan

Tradenames:3
Patents:2
Applicants:14
NDAs:19
Drug Master File Entries: see list20
Suppliers / Packaging: see list19
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms Ltd
ZOLMITRIPTAN
zolmitriptan
TABLET;ORAL203772-001Sep 30, 2015RXNo► subscribe► subscribe
Glenmark Generics
ZOLMITRIPTAN
zolmitriptan
TABLET;ORAL201779-002May 14, 2013RXNo► subscribe► subscribe
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-003Sep 16, 2013RXNo6,750,237*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: zolmitriptan

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 19975,863,935*PED► subscribe
Astrazeneca
ZOMIG-ZMT
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL021231-001Feb 13, 20015,466,699*PED► subscribe
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 20035,466,699*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc